Rapid-acting insulin aspart launched

Fiasp is a formulation of insulin aspart that includes nicotinamide (vitamin B3) to increase the speed of absorption.

Transferring a patient from another type, brand or manufacturer of insulin to Fiasp may necessitate a change in dosage. | SCIENCE PHOTO LIBRARY
Transferring a patient from another type, brand or manufacturer of insulin to Fiasp may necessitate a change in dosage. | SCIENCE PHOTO LIBRARY

Fiasp can be administered up to two minutes before or, if necessary, up to 20 minutes after starting a meal.

In pharmacokinetic studies in patients with type I diabetes, the onset of appearance of insulin in the bloodstream was twice as fast with Fiasp as with NovoRapid insulin aspart (4 minutes vs 9 minutes).

In a 26-week study involving 1,143 patients with type I diabetes, Fiasp administered at mealtime provided significantly greater improvement in HbA1c from baseline to week 26 than mealtime NovoRapid (-3.46mmol/mol vs -1.84mmol/mol [-0.32% vs -0.17%]) and significantly lower 1-hour and 2-hour post-prandial glucose increments than mealtime NovoRapid (-0.84mmol/L and -0.29mmol/L vs 0.34mmol/L and 0.38mmol/L, respectively).

Fiasp has also been studied in patients with type II diabetes. In a study involving 689 patients, mealtime Fiasp met the primary objective of non-inferiority in HbA1c reduction at 26 weeks compared with mealtime NovoRapid (-15.10mmol/mol vs -14.86mmol/mol [-1.38% vs -1.36%]).

Hypoglycaemia may occur earlier with Fiasp than with other mealtime insulins because of its earlier onset of action. The time to onset must be taken into account when prescribing to patients with concomitant diseases or treatment that may cause delayed absorption of food.


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.